Tuberculosis Diagnostics Market Size, Share, Forecast, & Trends Analysis by Test Type (Mantoux, IGRA, Radiography Molecular Culture, Sputum Smear), End User (Hospital, Diagnostic Lab), Infection Stage

Description

List of Tables

Tuberculosis Diagnostics Market Size, Share, Forecast, & Trends Analysis by Test Type (Mantoux, IGRA, Radiography [X-ray, CT] Molecular [NAAT, WGS, Rapid] Culture, Sputum Smear), End User (Hospital, Diagnostic Lab), Infection Stage - Global Forecast to 2031

The tuberculosis diagnostics market is expected to reach $3.56 Billion by 2031, at a CAGR of 5.0% from 2024 to 2031. Following thorough secondary and primary research and in-depth analysis of the market scenario, the report discusses key industry drivers, restraints, challenges, opportunities, and trends

The growth of this market is driven by the rising prevalence of tuberculosis (TB) in low-and middle-income countries, the emergence of drug-resistant strains, and favorable initiatives for TB diagnosis and treatment. Moreover, initiatives by governments and organizations to raise awareness about tuberculosis are expected to generate growth opportunities for the players operating in the tuberculosis diagnostics market.

Based on test type, the market is segmented into skin test/Mantoux, radiographic tests, molecular tests, sputum smear microscopy, culture & drug resistance tests, and other test types. The molecular tests segment is projected to register the highest growth rate of 5.8% during the forecast period of 2024-2031. This segment's growth is driven by the high efficiency & accuracy of molecular tests, technological advancements in molecular diagnostic technology, increasing availability of molecular tests for TB, and initiatives by market players to introduce rapid molecular diagnostic tests for TB & drug resistance. Moreover, new guidelines by public organizations such as the WHO regarding molecular TB tests further drive the segment's growth. For instance, in March 2024, the WHO published recommendations on the use of a new class of diagnostic technologies: targeted next-generation sequencing (NGS) tests for the diagnosis of drug-resistant tuberculosis (TB).

Based on infection stage, the tuberculosis diagnostics market is segmented into active and latent. The active segment is expected to register the highest CAGR during the forecast period of 2024-2031. This growth can be attributed to the increasing prevalence of tuberculosis in low- and middle-income countries, aims and goals set by governments and public organizations to manage the TB burden, and growing instances of TB outbreaks.

Based on end user, the tuberculosis diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users. The diagnostic laboratories segment is expected to register the highest CAGR during the forecast period. This growth is driven by the increasing adoption of advanced technologies for TB diagnosis, including next-generation sequencing. Furthermore, diagnostic laboratories are more capable of investing in such technologies compared to clinics and small to medium-sized hospitals. Additionally, government and organizational initiatives aimed at raising awareness about tuberculosis further contribute to the segment's growth.

An in-depth analysis of the geographical scenario of the tuberculosis diagnostics market provides detailed qualitative and quantitative insights into five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of 34.1% of the global tuberculosis diagnostics market, followed by Europe and Asia-Pacific.

However, the market in Asia-Pacific is projected to register the highest CAGR during the forecast period. Within Asia-Pacific, India and China are expected to present significant growth opportunities for players in the tuberculosis diagnostic market due to their large populations, high incidence of tuberculosis cases, and rising investments in healthcare. Additionally, the strong economic growth in both countries enables substantial investments in healthcare infrastructure and advancing tuberculosis testing technologies.

Key companies operating in the tuberculosis diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), Abbott Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN GmbH (Germany), Hologic, Inc. (U.S.), bioMerieux SA (France), Danaher Corporation (U.S.), Oxford Immunotec Ltd. (U.K.), Hain Lifescience GmbH (Germany), Creative Diagnostics (U.S.).

Scope of the Report:

Tuberculosis Diagnostics Market Assessment-by Test Type

Skin Test/Mantoux
Interferon Gamma Release Assay
Radiographic Tests
- Chest X-rays
- Computed Tomography
Molecular Tests
- Rapid Diagnostic Tests
- Whole-genome Sequencing
- Nucleic Acid Amplification Test
- Other Molecular Tests (Sangers Sequencing, Pyrosequencing)
Sputum Smear Microscopy
Culture & Drug resistance
Other Test Types

(Note: Other Test Types include Urine Test, Breath Test, Cytokine Detection Assay, Cerebrospinal Fluid Test)

Tuberculosis Diagnostics Market Assessment-by Infection Stage

Active
Latent

Tuberculosis Diagnostics Market Assessment-by End User

Diagnostic Laboratories
Hospitals & Clinics
Other End Users

(Note: Other End Users include government, private organizations, and NGOs)

Tuberculosis Diagnostics Market Assessment-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe (RoE)
Asia-Pacific (APAC)
- Japan
- China
- India
- Indonesia
- Thailand
- Philippines
- Singapore
- South Korea
- Australia
- Rest of Asia-Pacific (RoAPAC)
Latin America
Middle East
Africa
- South Africa
- Kenya
- Nigeria
- Rest of Africa

Product Code: MRHC - 1041202

1. Overview

1.1. Market Definition and Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Process of Data Collection and Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders of The Industry
2.3. Market Sizing and Forecast
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
- 2.3.3. Market Share Analysis
2.4. Assumptions For the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Factors Affecting Market Growth
- 4.2.1. Market Dynamics
  - 4.2.1.1. Drivers
    - 4.2.1.1.1. Rising Prevalence of Tuberculosis in LMICs
    - 4.2.1.1.2. Emergence of Drug Resistant Strains
    - 4.2.1.1.3. Favorable Initiatives for TB Diagnosis and Treatment
  - 4.2.1.2. Restraints
    - 4.2.1.2.1. Problems Associated with TB Testing
    - 4.2.1.2.1.1. False Positives
    - 4.2.1.2.1.2. Delays in Test Results Due to Delay in Immune Reaction
    - 4.2.1.2.1.3. Poor Sensitivity of Tests
  - 4.2.1.3. Opportunities
    - 4.2.1.3.1. Initiatives by Governments and Organizations to Raise Awareness Regarding Tuberculosis
  - 4.2.1.4. Challenges
    - 4.2.1.4.1. Stigma Associated Regarding TB Patients
4.3. Trends
- 4.3.1. Emergence of Point-of-Care Testing
- 4.3.2. Biomarker Research for TB
4.4. Regulatory Analysis
4.5. Porters Five Forces Analysis
4.6. Product Pipeline Analysis
4.7. Fundings & Investment Analysis

5. Tuberculosis Diagnostics Market Assessment-by Test Type

5.1. Overview
5.2. Skin Test/Mantoux
5.3. Interferon Gamma Release Assay
5.4. Radiographic Tests
- 5.4.1. Chest X-rays
- 5.4.2. Computed Tomography
5.5. Molecular Tests
- 5.5.1. Rapid Diagnostic Tests
- 5.5.2. Whole Genome Sequencing
- 5.5.3. Nucleic Acid Amplification Test
- 5.5.4. Other Molecular Tests
5.6. Sputum Smear Microscopy
5.7. Culture & Drug Resistance
5.8. Other Test Types

6. Tuberculosis Diagnostics Market Assessment-by Infection Stage

6.1. Overview
6.2. Active
6.3. Latent

7. Tuberculosis Diagnostics Market Assessment-by End User

7.1. Overview
7.2. Diagnostic Laboratories
7.3. Hospitals & Clinics
7.4. Academic & Research Institutes
7.5. Other End Users

8. Tuberculosis Diagnostics Market Assessment-by Geography

8.1. Overview
8.2. North America
- 8.2.1. U.S.
- 8.2.2. Canada
8.3. Europe
- 8.3.1. Germany
- 8.3.2. France
- 8.3.3. U.K.
- 8.3.4. Italy
- 8.3.5. Spain
- 8.3.6. Rest of Europe
8.4. Asia-Pacific
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Indonesia
- 8.4.5. Thailand
- 8.4.6. Philippines
- 8.4.7. South Korea
- 8.4.8. Singapore
- 8.4.9. Australia
- 8.4.10. Rest of Asia-Pacific
8.5. Latin America
8.6. Middle East
8.7. Africa
- 8.7.1. South Africa
- 8.7.2. Nigeria
- 8.7.3. Kenya
- 8.7.4. Rest of Africa

9. Competition Analysis

9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
- 9.4.1. Industry Leaders
- 9.4.2. Market Differentiators
- 9.4.3. Vanguards
- 9.4.4. Emerging Companies
9.5. Market Share Analysis/Market Ranking, by Key Players (2023)

10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)

10.1. F. Hoffmann-La Roche Ltd.
10.2. Becton, Dickinson and Company
10.3. Abbott Laboratories, Inc.
10.4. Thermo Fisher Scientific, Inc.
10.5. QIAGEN GmbH
10.6. Hologic, Inc.
10.7. bioMerieux SA (France)
10.8. Danaher Corporation
10.9 Oxford Immunotec Ltd. (U.K.)
10.10. Hain Lifescience GmbH
10.11. Creative Diagnostics

(Note: SWOT analysis of the top 5 companies will be provided)

11. Appendix

11.1. Available Customization
11.2. Related Reports